CPAP vs. Mandibular Advancement: Two Different Physiological Strategies for Airway Stability

Kathleen Carson
Apr 4
6 min read

April 2026 | By Dr. Kathleen Carson, DDS

Founder, Oral-Vitality

Introduction

CPAP is widely considered the gold standard for obstructive sleep apnea, and oral appliance therapy is often framed as a "less effective alternative." This framing is misleading. While CPAP is more effective at reducing the apnea-hypopnea index, mandibular advancement devices (MADs) achieve comparable improvements in patient-centered outcomes such as sleepiness and quality of life likely because patients use them more consistently.[1][2] These therapies do not work in the same way. They target airway stability through fundamentally different physiological mechanisms, and understanding this distinction is essential for appropriate treatment selection.

What's Happening Physiologically

CPAP applies positive pressure to pneumatically splint the airway, overriding airway collapsibility regardless of anatomy. It is an external force that bypasses the structural problem. MAD therapy, in contrast, reduces airway collapsibility by modifying structure. Mandibular advancement reduces pharyngeal collapsibility in a dose-dependent manner, with critical closing pressure (Pcrit) decreasing from 1.8 ± 3.9 cmH₂O at baseline to -4.0 ± 3.6 cmH₂O at maximum advancement.[3] Importantly, the primary mode of action is via improvement in passive pharyngeal anatomy, not changes in genioglossus muscle function.[3] This means MAD works by lowering Pcrit through mandibular positioning during use it improves passive pharyngeal anatomy while worn, though long-term therapy may produce gradual dentoalveolar changes that require monitoring.

The key distinction is this: CPAP represents external force applied to the airway, while MAD represents internal anatomical modification during therapy.

Why This Matters Systemically

Both therapies improve airflow and oxygenation, but their systemic interaction and real-world effectiveness differ in important ways. CPAP is highly effective when used and more efficacious at reducing AHI, but it is dependent on adherence and does not modify underlying anatomy. MAD may produce less maximal effect on AHI reduction, but often achieves higher adherence and works with the patient's anatomy. MADs are most effective in patients whose OSA is due primarily to anatomically narrowed upper airway.[4]

This creates a real-world paradox between efficacy and effectiveness. CPAP reduces AHI by approximately 6.2 events/hour more than MADs, but MAD adherence is better by 0.7 hours per night.[5] The greater efficacy of CPAP is offset by inferior compliance relative to MAD, resulting in similar effectiveness.[6] Meta-analysis shows MAD users average 0.70 hours more per night than CPAP users, with one study finding CPAP was used 3.6 ± 0.3 hours/night compared to 5.5 ± 0.3 hours/night with MADs.[5]

From a cardiovascular perspective, meta-analyses including 51 studies and 4,888 patients show both CPAP and MADs are associated with reductions in blood pressure, without any differences between the two therapies in terms of blood pressure outcomes.[4][7] A recent trial in severe OSA even showed MAD treatment reduced asleep mean blood pressure by -4.7 mm Hg, while CPAP showed no significant changes.[8] Both treatments significantly enhance patient outcomes, but adherence plays a crucial role in determining long-term success.[1]

Practical Application

Treatment selection should be individualized based on patient phenotype, preferences, and likelihood of adherence. The American Academy of Sleep Medicine guidelines recommend MADs across the range of OSA severity, not just for mild-moderate disease.[4][5] The evidence supports the following approach:

For mild OSA, limited data suggest no difference in clinical effectiveness between CPAP and MAD, making MADs a viable first-line therapy.[9] For moderate OSA, MADs achieve similar patient-centered outcomes to CPAP (sleepiness, quality of life) despite less AHI reduction.[2][6] For severe OSA, recent evidence shows titratable MADs have similar impact to CPAP on major patient-centered outcomes (sleepiness and quality of life), with treatment adherence and preference largely in favor of MAD. A 2025 study showed MAD adherence of 5.4 hours/night (56.1% using ≥6 hours/night) versus CPAP 4.9 hours/night (28.3% using ≥6 hours/night).[2][8]

Patient selection can be further refined by considering predictive factors. Meta-analysis shows that MAD responders tend to be younger, have smaller neck circumference, lower BMI, and positional OSA.[10][7] Patients with complete concentric palatal collapse during drug-induced sleep endoscopy (DISE) show lower response rates, while those with tongue base collapse are more likely to respond successfully.[4][11] Emerging evidence suggests that DISE-guided MAD therapy achieves higher success rates (82.7% vs 60.1%) by identifying favorable upper airway collapse patterns.[11]

Contraindications should also be considered. Absolute contraindications exist in approximately 34% of patients, primarily due to insufficient teeth to support the device, with periodontal problems coexisting in about half of contraindicated patients.[12] MADs are particularly appropriate for patients who prefer alternate therapy or are CPAP-intolerant, and they represent an acceptable and effective treatment even in severe OSA patients.[8][9][5]

Follow-up sleep testing with the MAD in place is essential to assess treatment efficacy, as subjective feedback is insufficient to optimize the device setting.[9] Treatment success is not just physiological it is behavioral. A therapy that is highly efficacious but poorly tolerated may be less effective in practice than a moderately efficacious therapy that patients use consistently.

Oral-Vitality Framework Integration

Within the Oral-Vitality framework, CPAP and MAD represent different approaches to the intersection of structure, sleep, and function. Structurally, MAD modifies mandibular position and improves passive pharyngeal anatomy during use, while CPAP bypasses anatomical limitations entirely. From a sleep standpoint, both improve respiratory stability and sleep architecture, with similar increases in N3 and REM sleep.[2] Functionally, MAD integrates with the patient's physiology by working through anatomical positioning, while CPAP imposes external support that is independent of anatomy.

This is exactly why oral-systemic care matters. MAD therapy is not just improving airflow it is interacting with a living, adaptive system that includes the airway, dentition, occlusion, and temporomandibular structures. That system requires monitoring and follow-up to ensure long-term sustainability.

Bottom Line

CPAP and MAD are not interchangeable therapies. They are complementary strategies that work through different physiological mechanisms. CPAP provides superior AHI reduction through external airway support, while MAD achieves comparable patient-centered outcomes through anatomical modification and superior adherence. The best approach depends on patient physiology, anatomical phenotype, tolerance, and likelihood of long-term use. Both represent valid first-line options across the severity spectrum when treatment selection is individualized and outcomes are monitored objectively.